Theriva Biologics, Inc. (TOVX) stock
TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.14+0.00 (+2.86%)
Close on Nov 18, 2026Market cap $6.61MP/E –Yield –
Theriva Biologics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Theriva Biologics's operating income for the twelve months ending Jun 30, 2026 was -$11.93M. For fiscal 2025 it was -$24.05M. The highest annual figure on record is -$10.16M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.05M | – |
| FY2024 | Dec 31, 2024 | -$26.35M | – |
| FY2023 | Dec 31, 2023 | -$21.43M | – |
| FY2022 | Dec 31, 2022 | -$21.58M | – |
| FY2021 | Dec 31, 2021 | -$14.27M | – |
| FY2020 | Dec 31, 2020 | -$10.16M | – |
| FY2019 | Dec 31, 2019 | -$15.66M | – |
| FY2018 | Dec 31, 2018 | -$17.57M | – |
| FY2017 | Dec 31, 2017 | -$26.25M | – |
| FY2016 | Dec 31, 2016 | -$39.25M | – |
| FY2015 | Dec 31, 2015 | -$40.98M | – |
| FY2014 | Dec 31, 2014 | -$20.50M | – |
| FY2013 | Dec 31, 2013 | -$12.34M | – |
| FY2012 | Dec 31, 2012 | -$17.30M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.30M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.13M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.22M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.03M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.13M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.11M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.89M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.21M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.24M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.32M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.99M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.78M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.84M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.48M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.15M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.20M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.16M | – |
See a number that looks wrong?